Epidemiology of Ozempic Poisoning

Semaglutide (Ozempic) has gained attention for its weight-loss effects, which has led to increasing off-label use for weight management. However, Ozempic is FDA-approved for managing T2DM and cardiovascular risks, not specifically for weight loss. The FDA-approved weight-loss medication containing semaglutide is Wegovy, which is administered at a higher dose. Misuse of Ozempic for weight loss outside its approved indication, particularly without medical supervision, can increase the risk of adverse effects, including severe gastrointestinal distress and hypoglycemia.
Semaglutide overdose is uncommon due to its prescription-only status and the emphasis on patient education for proper dosing. However, with increasing global demand and the drug's off-label use for weight management, cases of accidental and intentional misuse are emerging. Most reported exposures are therapeutic errors, such as incorrect dosing or dosing frequency, particularly during the initiation or dose escalation phases (Cairns & Buckley, 2023). Intentional misuse is less common but often linked to the growing popularity of semaglutide for weight loss due to its high efficacy in reducing body weight (Dhar et al., 2024).

Overdose effects primarily reflect an amplification of the drug's known side effects, including significant gastrointestinal disturbances (nausea, vomiting, diarrhea) and metabolic disruptions such as hypoglycemia or, in rare cases, acute kidney injury. These effects are more pronounced in cases of polypharmacy, particularly when semaglutide is combined with other medications like insulin or sulfonylureas (Barney et al., 2024).

Notably, increased public and social media attention has exacerbated inappropriate use, with some patients obtaining semaglutide for non-medical purposes. This misuse has contributed to supply shortages and increased the potential for errors during unsupervised administration (Mailhac et al., 2024).

Continued vigilance, patient education, and improved regulatory measures are critical to mitigating the risks associated with semaglutide misuse and overdose.

Pharmacokinetics of Ozempic (Semaglutide)

1. Absorption and Peak Concentration:

   • Route: Administered subcutaneously.

   • Bioavailability: Approximately 89%, ensuring consistent therapeutic effects with minimal variability (Dhillon, 2018).

   • Peak Concentration: Achieved within 24–48 hours post-dose, contributing to its predictable pharmacodynamic profile.

2. Metabolism:

   • Ozempic is extensively metabolized by protein hydrolysis into small peptides and amino acids.

   • Unlike many drugs, it bypasses the cytochrome P450 (CYP450) enzyme system, reducing risks of drug-drug interactions (Dhillon, 2018).

3. Half-Life:

   • Ozempic has an extended half-life of approximately 7 days, which allows for once-weekly dosing. This improves adherence and convenience for patients with type 2 diabetes and obesity (Feier et al., 2024).

4. Excretion:

   • The drug is primarily excreted via urine and feces as small peptides or amino acids, consistent with its metabolic breakdown (Dhillon, 2018).

5. Clinical Implications:

   • Ozempic's high bioavailability and long half-life ensure stable plasma concentrations, reducing fluctuations and providing sustained glycemic control over the dosing interval. This pharmacokinetic profile supports its efficacy in improving HbA1c levels and facilitating weight loss (Dhillon, 2018).

Mechanisms of action of Ozempic (Semaglutide)

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily acts by:

1. Enhancing Glucose-Dependent Insulin Secretion:

   • Increases insulin release only in elevated blood glucose, reducing the risk of hypoglycemia under normal conditions. However, in overdose or when combined with insulin or sulfonylureas, excessive insulin secretion can lead to severe hypoglycemia.

2. Delaying Gastric Emptying:

   • Slows gastric motility, promoting satiety and reduced caloric intake. In toxicity, this can lead to significant gastrointestinal distress, including nausea, vomiting, abdominal bloating, and discomfort.

3. Suppressing Glucagon Secretion:

   • Inhibits glucagon release, stabilizing blood glucose. Excessive suppression can exacerbate hypoglycemia, particularly in patients with insufficient glycogen stores or on glucose-lowering medications.

Mechanisms of Toxicity:

When Ozempic’s pharmacological effects are exaggerated, the following toxicities can occur:

1. Gastrointestinal Toxicity:

   • The most common and dose-limiting adverse effects. Overdose can intensify nausea, vomiting, diarrhea, and abdominal pain due to delayed gastric emptying and stimulation of gut motility receptors.

2. Electrolyte Imbalances:

   • Persistent vomiting and diarrhea can result in dehydration, hypokalemia, and hyponatremia, contributing to cardiovascular instability.

3. Severe Hypoglycemia:

   • Although rare when Ozempic is used alone, combining it with insulin or sulfonylureas in overdose scenarios can lead to profound hypoglycemia.

4. Pancreatic Stress:

   • Chronic or excessive stimulation of GLP-1 receptors may exacerbate underlying pancreatic conditions. While acute pancreatitis is rare, it has been reported and remains a concern during toxicity.

5. Renal Effects:

   • Dehydration from severe gastrointestinal symptoms can precipitate acute kidney injury, especially in patients with pre-existing renal impairment or other risk factors (Barney et al., 2024).

Therapeutic Dose of Ozempic:

• The FDA-approved dosing for Ozempic is 0.25–1 mg once weekly, with dose titration based on individual tolerance and glycemic control needs (Dhillon, 2018).

  Toxic Dose of Ozempic:

• The specific toxic dose for Ozempic is not well-defined in clinical literature. However, doses exceeding the recommended therapeutic range may intensify its pharmacological effects, causing toxicity. This is particularly true for individuals with comorbidities, renal impairment, or those on concurrent medications such as insulin or sulfonylureas.

• Reported Cases:

  Studies on semaglutide exposures, such as those from poison centers, reveal that therapeutic errors (e.g., incorrect dosing or dose escalation) are the most common cause of adverse effects (Cairns & Buckley, 2023). Intentional overdoses are rarer but could result in severe toxicity.

Threshold of Concern:

• While no exact toxic dose is established, doses significantly higher than 1 mg weekly are likely to increase the risk of severe adverse events. This risk is exacerbated in populations with comorbidities or polypharmacy.

Sources for Ozempic Use and Misuse

1. Prescription Use:

   • Ozempic (semaglutide) is FDA-approved for managing type 2 diabetes mellitus. It is administered as a once-weekly subcutaneous injection at doses ranging from 0.25 mg to 1 mg, titrated based on patient needs (Dhillon, 2018).

   • Its therapeutic effects include improved glycemic control and secondary benefits such as weight reduction, making it a valuable option for overweight diabetic patients.

2. Common Misuse:

   • Off-Label Weight Loss: Ozempic is frequently misused for weight loss in individuals without diabetes, largely influenced by social media promotion and public interest in its weight-reduction effects (Cairns & Buckley, 2023).

   • Self-Dosing and Overdosing: Some individuals exceed prescribed dosages or self-administer Ozempic without medical supervision to accelerate weight loss, leading to adverse effects such as severe gastrointestinal distress and, in rare cases, hypoglycemia (Dhar et al., 2024).

3. Clinical Concerns:

   • Therapeutic Errors: Incorrect dose escalation or administration frequency is common, particularly during the initiation phase.

   • Drug Shortages: Widespread misuse of Ozempic for weight loss has contributed to global supply shortages, limiting access for diabetic patients (Mailhac et al., 2024).

Ozempic is a critical treatment for type 2 diabetes but has been misused for weight loss due to its secondary benefits. Misuse, particularly unsupervised self-dosing, increases the risk of adverse effects and exacerbates drug shortages. Proper education and monitoring are essential to mitigate these challenges.

Therapeutic and Toxic Serum Concentrations

• Therapeutic Serum Level: Not routinely measured. Clinical effects are dose-dependent.

• Toxic Serum Level: Undefined, though toxic effects are expected at doses significantly higher than therapeutic recommendations.

Clinical Presentation and Signs and Symptoms of Ozempic Toxicity Based on Severity

Mild Ozempic Toxicity

1. Symptoms: Nausea, vomiting, diarrhea, mild abdominal pain or bloating, dizziness, or fatigue

   • These are widely reported as common adverse effects of semaglutide. Gastrointestinal symptoms like nausea, diarrhea, and vomiting are noted as prevalent adverse events in patients treated with semaglutide (Feier et al., 2024).

Moderate Ozempic Toxicity

2. Symptoms: Persistent vomiting with dehydration, hypoglycemia, moderate abdominal distension or cramping

   • Persistent vomiting leading to dehydration is plausible, especially since nausea and vomiting are common. Hypoglycemia is noted in some cases, particularly when semaglutide is combined with insulin or sulfonylureas (Feier et al., 2024).

   • Moderate abdominal cramping or distension aligns with gastrointestinal effects reported in semaglutide users.

Severe Ozempic Toxicity

3. Symptoms: Electrolyte imbalances, severe hypoglycemia or hyperglycemia, acute pancreatitis, cardiovascular symptoms

   • Electrolyte Imbalances: While specific cases of electrolyte derangements like hypokalemia or hyponatremia are not directly tied to semaglutide in the available literature, dehydration secondary to persistent gastrointestinal symptoms could lead to such imbalances.

   • Acute Pancreatitis: Acute pancreatitis is a rare but recognized risk associated with GLP-1 receptor agonists, including semaglutide (Feier et al., 2024). Severe abdominal pain and elevated lipase levels support this association.

   • Cardiovascular Symptoms: Tachycardia and hypotension could result from dehydration or severe hypoglycemia.

Management of Ozempic Toxicity Based on Severity

Management of Mild Ozempic Toxicity Management

1. Supportive Care: Encourage oral hydration to prevent dehydration from gastrointestinal symptoms.

2. Antiemetics: Administer antiemetic medications (e.g., ondansetron) for nausea or vomiting.

3. Monitoring: Observe for resolution of symptoms within 24–48 hours. Reassess if symptoms persist or worsen.

Management of Moderate Ozempic Toxicity Management

1. IV Fluids: Administer intravenous fluids to correct dehydration and prevent further electrolyte imbalances.

2. Electrolyte Monitoring: If imbalances are identified, monitor and correct electrolytes, especially potassium, sodium, and chloride.

3. Blood Glucose Monitoring: Perform frequent blood glucose checks, especially if hypoglycemia is suspected, particularly in patients on insulin or sulfonylureas.

4. Antiemetics: Continue or escalate antiemetic therapy for persistent vomiting (e.g., ondansetron or metoclopramide).

Management of Severe Ozempic Toxicity Management

• Hospitalization: Admit the patient for continuous monitoring and aggressive intervention.

  1. Electrolyte Replacement:

     Administer IV potassium, sodium, or other electrolytes to correct significant imbalances.

  2. Pancreatitis Management:

     • For suspected or confirmed acute pancreatitis (e.g., severe abdominal pain, elevated lipase levels), initiate supportive care:

       • NPO (nil per os): Keep the patient fasting to reduce pancreatic stimulation.

       • IV hydration: Use isotonic fluids to maintain perfusion and correct dehydration.

       • Consider pain management with non-opioid or opioid analgesics if necessary.

  3. Cardiovascular Support:

     • Treat tachycardia or hypotension with fluid resuscitation and, if needed, vasopressors under intensive care.

  4. Specialized Monitoring: Ensure close observation of vital signs, renal function, and cardiac status.

Antidote

• No specific antidote for semaglutide overdose.

• Management is primarily supportive and symptomatic.

Children

1. Observation Duration:

   • Observe for 12–24 hours if exposure is suspected due to improper administration (e.g., accidental overdose via injection or frequency error) or secondary exposure through contact with medication.

   • Extend observation if symptoms persist, especially considering the long half-life of semaglutide (~7 days).

2. Monitoring Focus:

   • Hypoglycemia: Monitor blood glucose levels closely, particularly in children who may have received an excessive dose or are more vulnerable due to lower glycogen reserves. Regular checks every 2–4 hours are recommended.

   • Dehydration: Assess hydration status, particularly if exposure leads to significant gastrointestinal symptoms like nausea, vomiting, or diarrhea.

   • Injection Site Reactions: Check for localized swelling, erythema, or pain resulting from improper administration.

Adults

1. Observation Duration:

   • Observe for at least 8–12 hours post-exposure.

   • Prolonged observation may be necessary for significant overdoses due to the long elimination half-life (~7 days), which can cause persistent or delayed toxicity.

2. Monitoring Focus:

   • Electrolyte Imbalances: Regularly check serum potassium, sodium, and chloride if significant vomiting or diarrhea occurs.

   • Blood Glucose Levels: Continuous monitoring for hypoglycemia, especially in patients on insulin or sulfonylureas.

3. Key Considerations:

   • Symptoms such as severe nausea, vomiting, and hypoglycemia may manifest later due to delayed gastric emptying and prolonged receptor activation.

   • In prolonged toxicity or worsening symptoms, admit for further evaluation and management.

Prevention and Public Health Measures for Ozempic (Semaglutide) Toxicity

1. Patient Education:

   • Provide clear instructions on proper use: Ensure patients understand the prescribed dosing regimen and the importance of adhering to it.

   • Educate on storage: Recommend keeping Ozempic in a refrigerator and away from light until ready.

   • Discuss disposal: Inform patients about properly disposing of unused or expired Ozempic to prevent accidental exposure or misuse.

2. Prescriber Oversight:

   • Limit prescriptions to therapeutic doses based on FDA-approved indications.

   • For patients seeking Ozempic for off-label weight management, carefully assess risks and benefits while adhering to clinical guidelines.

   • Regularly monitor patients for side effects and compliance during follow-up visits.

3. Misuse Prevention:

   • Awareness Campaigns: Educate the public about the risks associated with inappropriate use of semaglutide for weight loss, particularly through social media platforms.

   • Collaborate with health organizations to address growing trends in off-label use and promote evidence-based guidance for obesity management.

4. Safe Storage:

   • Advise patients to store medications out of reach of children to prevent accidental exposure.

   • Highlight the importance of secure storage for individuals at risk of intentional overdose, such as those with a history of mental health challenges.

5. Regulatory Measures:

   • Implement restrictions or warnings on prescriptions for non-approved uses to mitigate misuse.

   • Encourage pharmacies to verify prescriptions for off-label indications and educate patients on appropriate use.

6. Healthcare Provider Training:

   • Train healthcare providers to recognize early signs of semaglutide misuse and educate patients about potential side effects.

   • Encourage providers to report adverse events to pharmacovigilance systems to improve safety data collection.